Return to homepagePandemic Pact

To rapidly identify a human monoclonal antibody that potently neutralizes SARS-CoV-2 and that is suitable for clinical development for prevention and treatment of COVID-19 based on convalescent serum screening.

  • Funded by Emergent Ventures Fast Grants
  • Total publications:0 publications

Grant number: unknown

Grant search

Key facts

  • Disease

    COVID-19

  • Funder

    Emergent Ventures Fast Grants

  • Principal Investigator

    Dr. Davide F Robbiani

  • Research Location

    United States of America

  • Lead Research Institution

    The Rockefeller University

  • Research Priority Alignment

    N/A

  • Research Category

    Therapeutics research, development and implementation

  • Research Subcategory

    Pre-clinical studies

  • Special Interest Tags

    N/A

  • Study Type

    Unspecified

  • Clinical Trial Details

    N/A

  • Broad Policy Alignment

    Pending

  • Age Group

    Unspecified

  • Vulnerable Population

    Unspecified

  • Occupations of Interest

    Unspecified

Abstract

To rapidly identify a human monoclonal antibody that potently neutralizes SARS-CoV-2 and that is suitable for clinical development for prevention and treatment of COVID-19 based on convalescent serum screening.